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Human Papillomavirus Infections in
Incarcerated Women
The factors associated with the development of
lower genital tract neoplasia (cancers) are
directly related to lifestyle, poverty, sexual risk
taking behaviors, and access to health care.
Historically it has been observed that women
who have multiple sexual partners or have a
partner who has had multiple sexual partners
are at highest risk for the development of cervi-
cal cancer. Human papillomavirus (HPV) is the
most important etiological agent in neoplastic
change. In the past two decades, HIV and HPV
co-infection has been associated with more
rapid development of cervical cancer. Most
incarcerated women are at very high risk for cer-
vical cancer due to their lifestyles and to the high
rate of HIV co-infection in this population. This
paper reviews the present knowledge of this viral
infection and the management of HPV infection
in incarcerated populations.
EPIDEMIOLOGY
Human papillomavirus (HPV) is a sexually trans-
mitted disease. The role of HPV in malignant
transformation has become fairly well-estab-
lished. HPV DNA has been found in over 95% of
cervical condyloma accuminata, all premalignant
cervical lesions, and invasive cancers. Due to
poor access to preventive health care in devel-
oping countries of the world and in selected pop-
ulations in the developed world, cervical cancer
remains the leading cause of cancer death
world-wide.
An accurate evaluation of the prevalence of
human papillomavirus infections is difficult
because the infection is not reportable, most
infections are subclinical, sensitivity of detection
varies with the method used, and regression of
infection occurs. However, HPV is thought to be
the most common viral sexually transmitted dis-
ease. It is estimated that 20 to 40 million per-
sons in the United States are infected with HPV.
HPV is very common, as can be demonstrated
by studies of mass screening using hybridization
techniques on cells collected from cervical
smears. Ten to 30 percent of specimens had
evidence of HPV infection. The Centers for
Disease Control and Prevention (CDC) have
observed an increase in the prevalence of HPV
infection obtained through surveys of office visits
for HPV from 1966 to 1988: a five fold increase
occurred during that period. In some popula-
tions, cross sectional studies of cytologically
normal women suggest that 20 to 40 percent of
sexually active women have detectable HPV
infection. That prevalence decreases with age.
HPV is classified by subtype. Some subtypes
are more or less likely to be associated with cer-
vical cancer. Genital subtypes can vary by geog-
raphy and ethnicity. In the United States, HPV
16 has been found to be the most prevalent sub-
type. HPV 16 is also the predominant subtype in
countries around the world except for Indonesia,
where HPV 18 is more common. There is sig-
nificant geographic variation in the prevalence of
some of the less common viral subtypes. A clus-
tering of HPV 45 has been apparent in Western
Africa, while HPV 39 and HPV 59 have been
almost entirely confined to Central and South
America.
Most HPV infections occur in young adults with
a peak in the late teens and early twenties.
Currently HPV infections have reached epidem-
ic proportions in young, sexually active popula-
tions. Of note, the mean age for women who
develop cervical dysplasia is 25 years old, while
carcinoma-in-situ and invasive cervical cancer
has an older mean age of 30 and 50 years
respectively. The decreasing prevalence of
human papillomaviral infections with age is
thought to be related to increasing development
of both cell mediated immunity and mucosal IgA
immunity.
Human papillomavirus infection is predominant-
ly transmitted by micro trauma to the genital
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mucosa that occurs as part of normal sex-
ual behavior. Viral particles are introduced
in this way in the basement membrane of
the skin. Over two-thirds of partners of
persons infected with HPV developed
condylomata on average two to three
months after exposure. Transmission
occurs from male to female, female to
male, male to male, and female to female.
PCR studies suggest all coital contacts are
infected with one exposure. The incubation
period is long, and can be difficult to accu-
rately assess because of subclinical infec-
tions and the effect of host immunity. It is
estimated to be anywhere from three
weeks to 20 months. While condoms are
thought to be slightly protective for cervical
infections by HPV, they are not protective
against transmission from contact between
external genital skin. Human papilloma
virus can also be transmitted vertically dur-
ing childbirth. Juvenile laryngeal papillo-
matosis is a rare sequellum of vaginal
delivery. Other potential modes of trans-
mission have not been well-documented.
These include fomites and close, non-sex-
ual contact such as with children. Co-fac-
tors for transmission, persistence, and neo-
plastic change in HPV infections include
tobacco use, oral contraceptives, and pos-
sibly concurrent sexually transmitted dis-
eases such as herpes simplex, chlamydia
trachomatis, cytomegalovirus, and Epstein-
Barr virus.
PATHOGENEIS AND 
NATURAL HISTORY
While 30 to 50% of sexually active people
are infected with human papillomavirus,
progression to cancer occurs in less than
one percent of women. There are three
possible scenarios for a HPV infection.
There can be complete clearance of HPV
after the acute infection. Alternatively, the
infection can stay or become latent. And
finally, there can be active progression of
the infection. Observations supporting the
transient nature of some infections include
the increase of host immunity with age, and
the anatomical changes in the normal mat-
uration of the cervix. In the teenage and
young adult group, the glandular endocer-
vical lining is present on the exocervix
(called cervical ectropion). As the cervix
matures over a woman’s reproductive life,
the cervical ectropion is replaced through a
process of squamous metaplasia to strati-
fied squamous epithelium. The stratified
squamous epithelium is thought to be more
protective in general against sexually trans-
mitted diseases. Hormonal environment
may also play a role in the patient’s sus-
ceptibility to HPV. Mucosal immunity
occurs through the common mucosal
immune system with production of IgA over
time. This is a slow delayed response that
does not immediately occur with initial
exposure to HPV. Risk factors for persis-
tent HPV infection and neoplastic change
include aneuploid dysplastic lesions, onco-
genic HPV subtypes, immunosuppression,
and certain HLA alleles.
CLINICAL MANIFESTATIONS
OF HPV INFECTION
BENIGN LESIONS
A vulvar condyloma can show a wide range
of appearances. Small raised crusted
lesions can appear on the vulvar or peri-
anal region. Bigger condyloma can appear
confluent, rising above the skin level. In
immunocomprised patients, the condyloma
can extend up onto the mons and back to
the buttocks. Small papular changes on
the skin can sometimes be attributed to
HPV infection. These visual changes can
either be completely asymptomatic or can
be associated with vulvar pruritis and burn-
ing. Exophytic condyloma can also occur in
a multifocal pattern in the vagina.
Condyloma can also occur on the cervix.
The majority of cervical condyloma are flat
although raised leukoplakic lesions can be
seen.
PREMALIGNANT LESIONS
Intraepithelial neoplasia of the lower genital
tract can be categorized by site. Vulvar
intraepithelial neoplasm (VIN) appears as a
discrete pigment change on the vulvar skin.
This pigment change can be white, gray,
black or red. Most commonly it is gray to
black. The lesion may or may not be raised
but always has a sharp border to it. VIN is
commonly multifocal and frequently
involves the perianal region as well. These
lesions can be completely asymptomatic or
can be associated with burning or itching.
Vaginal intraepithelial neoplasia (VAIN) is
an aymptomatic mucosal change that can
occur anywhere in the vagina. It is seen by
colposcopic viewing as discrete, sharp bor-
dered regions of white epithelium that may
or may not be associated with atypical vas-
cular changes. Cervical intraepithelial neo-
plasia (CIN) is also asymptomatic. This
can appear as unifocal or multifocal white,
discrete lesions seen by colposcopy.
These lesions can be associated with atyp-
ical blood vessels such as a mosaic (cob-
blestone) or punctate vascular pattern. All
intraepithelial neoplasia can be divided into
low grade or high grade lesions. Low grade
lesions are usually histopathologically
associated with cytopathic changes of
HPV. High grade lesions include moderate
to severely dysplastic changes.
MALIGNANT LESIONS
Invasive cancers of the lower genital tract,
which include anal, vulvar, vaginal, and
cervical cancers, have all been associated
with human papillomavirus infections.
Perianal cancers are highly associated with
immunosuppression such as that observed
in progressive HIV infection. Invasive vul-
var cancers have a bimodal age distribu-
tion. In the younger age group, mean age
40 years, vulvar cancer is highly associat-
ed with HPV infection. These lesions are
usually multifocal and can be associated
with immunosuppression from HIV. The
second age group (mean of 70 years),
have unifocal vulvar cancers that are not
HPV related. Vulvar and perianal cancers
can appear as a raised or ulcerated lesion
on the surface of the skin. Very small can-
cers may be asymptomatic. However with
time, these cancers become painful and
can bleed.
Vaginal cancers comprise one percent of
all female genital malignancies. They are
associated with HPV infection. The most
common site of vaginal cancer is the pos-
terior upper third of the vagina. Frequently
these cancers are missed when they are
small as they can be hidden by the specu-
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Table 1: HPV Subtypes and Associations with Mucosal Neoplasia
LOW RISK
G 6, 11 - cause papillomas of the upper airways and external genital condyloma
G 42, 43, 44 - closely related in their nucleotide sequence to 6, 11
INTERMEDIATE RISK
G 31, 33, 35, 51, 52 - associated with dysplasia
HIGH RISK
G 16 - present in 50% of high grade squamous intraepithelial lesions of the
cervix, and invasive cancer present in 15% to 40% of low grade lesions in the
cervix, present in 85% of high grade lesions in other areas of the anogenital
tract, present in 40% of subclinical lesions of the vulva and 10% of recalcitrant
condyloma acuminate
G 18 - very rarely found in low grade lesions. Involved in a faster transit time to
invasive cancer in squamous and glandular lesions, closely linked to glandular
dysplasia and adenocarcinoma of the cervix
Dear Colleagues,
Having just returned from a trip to visit the University of Mali Medical School, hospital (Point
G) and research center (the NIH-funded MRTC) in Bamako, Mali (West Africa), I¹m looking at
the enormous contrast between HIV practice here, and there, from a new perspective. As there
is still only limited access to antiretroviral agents, and the cost of the medication is still prohib-
itive despite a dramatic pricing reduction, patients are reluctant to get tested for HIV (why test,
if treatment is inaccessible). Therefore, most patients only present to clinicians in the very late
stages of AIDS - literally on death¹s door. The real tragedy is yet to come, when the effect of
AIDS on the economic stability of subsaharan Africa becomes more apparent. The average
age of the AIDS ward patients when I visited was 23.
I saw cases of severe cryptococcal meningitis, wasting disease, and miliary tuberculosis, the
likes of which I have not seen in years in my practice here in the US. Screening for and treat-
ment of CMV is unheard of Mycobacterial subtyping (MAI vs M.tb vs M.bovis) is not possible.
Prophylaxis for opportunistic infections is not feasible, due to the cost of the medications. And,
to put the conditions for patients in sharp contrast with the treatment for HPV that is outlined
in this issue of HEPP by my colleague A.K. Goodman, Pap testing is not the standard of care-
at all. Thus, cervical cancer is one of the top cancer causes of death in Africa.
I am pleased to report that antiretroviral medication ("ARV" to Malian doctors) is becoming
more accessible due to the advocacy of clinicians and governments in Africa, and Malian
physicians are eager participants in any AIDS training courses that are available. I hope we
may help our colleagues avoid some of the costly errors we have made in the course of the
US epidemic. How would we structure HIV/AIDS care now, if we had a chance to start over
now that so many different treatment options are available?
Our tradition to address sexually transmitted diseases in our January issue of HEPP is done
by AK Goodman, a gyn-onc specialist who provided care contemporaneously with me in a MA
DOC institutions in the late 1980s. In this issue, Dr. Goodman provides a roadmap for the diag-
nosis and treatment of HPV. After reading this article, readers should understand the trans-
mission of HPV, the relative risk of the various subtypes, and the current gynecological stan-
dard of care for HIV-positive women. In keeping with the STD theme, we also bring you a spot-
light on the issue of condom distribution in prison and jail settings from across the border
(Canada). And, since the use of combination therapy is expanding, we decided to re-run our
"Abacavir Hypersensitivity Syndrome (AHS)" algorithm, which clinicians can use in order to
recognize the symptoms of AHS and to identify the antiretroviral medications that contain aba-
cavir.
Sincerely,
Anne S. De Groot, M.D.
Letter from the Editor
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4lum blades. Early cancers are asympto-
matic. As the cancer grows, the major symp-
toms become bleeding and pain. On physi-
cal examination, these cancers will appear
as discrete, raised, or ulcerated lesions that
are hard on palpation.
Cervical cancer is highly associated with
HPV infection. Asymptomatic cancers are
picked up by Pap smear screening. On
inspection, a cervical cancer can appear
exophytic with a polypoid, raised growth on
the exocervix, or endophytic, with expansion
of the cancer in the endocervical canal.
Early symptoms include post-coital spotting,
abnormal vaginal bleeding, and an abnormal
discharge. Late symptoms that herald
metastatic spread include bladder outlet
obstruction, constipation, back pain, and leg
swelling.
DIAGNOSIS
Diagnosis of HPV infection and its clinical
manifestations can be made by clinical
examination, HPV DNA detection methods,
cytology, and/or colposcopy with biopsy.
Most basic and clinical investigations use
one or more of three nucleic acid-based
tests to detect and type HPV. These tests
include hybrid capture system (HCS), in situ
hybridization (ISH), and polymerase chain
reaction (PCR). Presently hybrid capture II
assay is used commercially for clinical HPV
testing.
THE ROLE OF HPV TESTING
The role of HPV testing has been intensive-
ly evaluated. It has been looked at as an
adjunct to cervical cancer screening and as
a triage tool for low grade and atypical Pap
smears for colposcopic referrals. Three
recent studies have evaluated the utility of
HPV testing. A longitudinal cohort of 2011
women aged 15-19 was recruited by
Woodman et al. Testing and cytology was
performed every six months for three years.
The cumulative risk of any HPV infection
was 44% however most infections were of
short duration. Twenty-eight of the 2011
developed high grade dysplasia. They con-
cluded that the inevitability of acquiring an
HPV infection and the transient nature of the
infection made HPV testing for cervical can-
cer risk assessment inadequate.
A second study by Moscicki et al prospec-
tively screened 105 women who were HPV
negative at baseline for a median of 50
months. Nineteen percent developed low
grade dysplasia and no women developed
high grade dysplasia. They concluded that
the majority of young women with HPV
infection never develop low grade dysplasia.
Solomon et al reported their preliminary find-
ing from the ASCUS/LSIL Triage Study
(ALTS) trial. They looked at 3488 women
with atypical squamous cells of uncertain
significance (ASCUS) who were randomized
to immediate colposcopy, HPV triage, or
repeat Pap smear. They found that the
prevalence of high grade lesions was 5.1%.
However, 56.1% of the women with ASCUS
were positive for high risk HPV types. While
they concluded that HPV testing has a
greater sensitivity to detect a high grade
lesion compared with repeat Pap smear
alone, there was a significantly increased
number of women referred to colposcopy.
In conclusion, as most HPV infections are
transient and are not associated with neo-
plastic change, isolated HPV testing does
not accurately identify those women des-
tined to develop malignancy. At the present
time, HPV DNA testing cannot be recom-
mended for routine clinical use.
TREATMENT AND 
MANAGEMENT
The goal of treatment is to destroy visible
lesions for cosmetic reasons, reduction of
symptoms, or treatment of preinvasive and
invasive lesions. No treatment modality will
eradicate the virus. For benign condyloma
and preinvasive disease, local destruction
with podophyllin, trichloroacetic acid, laser,
or excision can be used. For invasive dis-
ease, either a radical surgical excision or
radiation therapy is used.
Because HIV infected and immunocompro-
mised patients have an increased incidence
of persistence and progression to neoplastic
change, they need to be monitored more
closely over time. For routine screening, at
least yearly Pap smears and visual inspec-
tion of the external genitalia should be per-
formed. For a number of reasons, including
poor follow-up care after release from
prison, the current standard of practice for
incarcerated HIV-infected women is to per-
form Pap smears every six months. Most
institutions have colposcopy available on
site. Some authors recommend a baseline
colposcopy for all HIV infected women with
the presence of HPV infection. There
appears to be a reduction of accuracy of Pap
smears in this group secondary to obscuring
inflammation from cervicitis. Colposcopy
should be done on all women with abnormal
Pap smears including atypia and low grade
dysplasia. All dysplasias should be treated
aggressively .
CONCLUSION
Human papillomavirus is a necessary but
not sufficient factor for the development of
lower genital tract neoplasia. Most HPV
infections are with the high risk oncogenic
subtype yet less than one percent of women
with this infection will experience a malig-
nant progression. Risk factors for progres-
sion to malignancy include immunosuppres-
sion and persistent HPV infection. Careful
screening with good physical examination
and Pap smear testing can detect most of
preinvasive and invasive lower genital tract
disease.
Human Papillomavirus...
(continued from page 2)
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5HEPPigram: Management of the Abacavir Hypersensitivity Syndrome (AHS)
Patient is within six weeks of starting ABC, has a skin rash or two or more of the following sets of symptoms that persist and
progress beyond 72-96 hours:
1. fever
2. nausea, vomiting, diarrhea or abdominal pain
3. myalgias, severe fatigue or malaise
Evaluate patient immediately. Evaluation should include blood pressure, examination for rash, chemistry profile and CBC.
Note: Symptoms may be indistinguishable from a viral syndrome, however usually do not include respiratory complaints.
See patient DAILY for next 72 hours.
Admission to medical infirmary may be indicated in some cases. Do NOT discontinue ABC at this time.
Prescribe antiemetics if nausea/vomiting is significant component of patient’s symptoms.
If AHS is suspected or diagnosed, NEVER re-challenge the patient with ABC. Mark chart as such and counsel patient to never
take ABC again. Note that both ZIAGEN and TRIZAVIR contain ABCand therefore chart must be clear: Patient has life-threatening
sensitivity to ABC in both Ziagen and Trizavir. Note: if patients stop ABC treatment for other reasons (e.g. non-adherence), they
CAN be restarted on ABC therapy.
Symptoms abate in 72-96 hours
Symptoms abate in 24-48 hours
Yes
Viral
Syndrome
No
Consider AHS. Stop ABC treatment.
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Approximately 3%-5% of patients who are on Abacavir (ABC) antiretroviral therapy experience what is known as the Abacavir
Hypersensitivity Syndrome (AHS) within the first six weeks of therapy. It is important to counsel patients about AHS before they begin
treatment and to contact medical staff immediately if symptoms should occur within the first six weeks of treatment. Additionally, they
should be counseled NOT to discontinue the medication on their own, as it would confuse later decision making. This algorithm
describes the management of AHS.
It is important NOT to stop the ABC when symptoms first appear, without further investigation as described above, as they are indis-
tinguishable from a viral syndrome. Because AHS is not dangerous if detected early, clinicians can have the opportunity to follow the
patient and determine if the patient’s symptoms disappear. If, on the other hand, the ABC is stopped before confirmation of AHS, it
could preclude the use of a truly potent antiretroviral that the patient might need in the future. Unfortunately, once stopped in the
event of symptoms, ABC can never be used again.
Spotlight: Condoms in Correctional Settings
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Wardens turned their eyes and minds west to Los Angeles last
month, after hearing that the Los Angeles County Jail (LACJ) began
distributing condoms to its self-declared gay inmates (see Inside
News, page 8). The LACJ is only the seventh facility in the nation to
distribute condoms. Four jail systems, in New York City, Philadelphia,
San Francisco, and Washington, and two prison systems, in Vermont
and Mississippi, also make condoms available to their inmates. Most
correctional facilities in the US have chosen not to distribute con-
doms due to three major concerns: 1) that condoms would be used
as weapons; 2) that the condoms would be used to hide contraband;
3) and/or that the distribution of condoms would implicitly suggest
that sex is permitted.
Condoms have been available in Canadian federal prisons for 10
years (condoms were first made available January 1, 1992).1 HEPP
News recently interviewed Mr. Ralf Jürgens, director of the Canadian
HIV/AIDS Legal Network about the Canadian experience with con-
dom distribution over the past decade.
Commonly voiced fears about making condoms available in prisons
include the fear that the condoms can and will be used as weapons.
One concern, mentioned by several correctional professionals in
response to the news about the LACJ is that condoms could be filled
with sand or dirt and used to hit other inmates or corrections staff.
Other professionals have raised concerns about condoms being
used as a strangulation device. When asked if these situations or
other situations similar to these have arisen in Canada, Jürgens
replied, “No. No events like these have been reported and further-
more, there have been no reported events of condoms being used
as any type of weapon.”
In fact, Jürgens explained, the “issues [surrounding condom distrib-
ution in corrections] have become non-issues.” Jürgens cited a sur-
vey he worked on as part of the Expert Committee on AIDS and
Prisons in Canada in 1995, several years after condoms were made
available (at that point condoms were available in a wide variety of
ways, not only through healthcare services). In this survey, the
researchers found that 82% of correctional staff reported that making
condoms available in prisons had not created any problems in the
institution.2 The 18% of staff who did report problems cited issues not
related to safety and security. There were comments, for example,
that the inmates were “using too many of them [condoms],” Jürgens
said, emphasizing that the problems reported were often minor and
in no way endangered either the staff or the inmates.
Furthermore, although some staff had been concerned that condoms
could be used to hide contraband or that making condoms available
would be seen as encouraging sexual activity, most staff found that
these fears did not materialize. According to Jürgens, the idea of
condoms being used to hide contraband was discussed before con-
doms were available, but there has been no mention of it since. As
Jürgens explained, condoms are not available from outside the pris-
ons, only from within the institution. Therefore, it makes it difficult, if
not impossible, to use condoms as containers in which to smuggle
contraband into the prison from outside. Furthermore, Jürgens said
that objects that constitute contraband have been smuggled from
location to location within the prisons long before condoms were
made available. In other words, although condoms could serve as
another way to hide and/or transport contraband once it is inside the
walls, they have not materialized as “contraband containers.”
The third issue surrounding the availability of condoms in corrections
is that it implies that sexual activity is permitted, when in fact, it is ille-
gal. Responding to this idea, Jürgens cited that sex while in prison
is still an institutional offense in Canada, but that “fighting the spread
of HIV is more important than upholding so-called morality when the
activity is occurring [even in the absence of condoms].” He made the
analogy that while drug use is illegal on the outside as well as on the
inside, many countries around the world have needle exchange pro-
grams, responding to a public health problem. Jürgens described the
availability of condoms in corrections as “a pragmatic public health
response to something that happens – it does not condone the activ-
ity [in itself].” Thus, in the Canadian experience, the issues most
often discussed regarding condoms in corrections have turned out
not be issues.
Although condoms have been available in Canadian federal prisons
since 1992, many inmates chose not to access condoms until 1994.
Jürgens and others questioned inmates about the distribution
process. Initially, condoms were only distributed in prison healthcare
services. Inmates responded that they would be much more likely to
use the condoms if they did not have to go to a health services
provider and ask for them, since doing so meant admitting to partic-
ipating in an activity that is specifically prohibited in every Canadian
correctional facility. Currently bowls or other containers filled with
condoms have been placed in areas where inmates can pick them
up without being seen by correctional staff or other inmates. Since
1994, condoms, dental dams, and lubricant have been made avail-
able in washrooms, shower areas, libraries, and in some cases are
freely available “on the ranges.” However, some facilities and a few
provincial correctional systems have elected not to provide condoms
at all or to provide them only through health services. Perhaps the
most important observation Jürgens provided on the Canadian expe-
rience is that none of the facilities that has ever adopted a policy to
make condoms available has reversed the policy.1
Jürgens also provided data from studies in Europe which have
revealed that the percentage of prison systems providing condoms
rose from 53% in 1989 to 81% in 1997.1 There are only four prison
systems in Europe that are not making condoms available to
inmates- the rest are now doing so. “The United States is one of the
few industrialized countries that do not make condoms available [to
inmates],” Jürgens said. The situation in corrections in the United
States does not exactly mirror that in Canada or in any other correc-
tional system worldwide, as each nation’s system is unique. Given
the higher proportion of inmates incarcerated for drug-related crimes
in the United States, consideration surrounding condom distribution
may differ than those in Canada. Furthermore, considerations for
condom distribution in prisons may differ from those for jails.
Nonetheless, arguments used in the United States to bar the distrib-
ution of condoms in correctional facilities are “not sustainable,”
according to Jürgens, given the widespread adoption of condom dis-
tribution in other developed nations of the world and the relatively
few problems as a result.
*Nothing to disclose.
By Rebecca Nerenberg*, Managing Editor, HEPP News
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REFERENCES:
1. The Canadian HIV/AIDS Legal Network. Prevention: Condoms. http://www.aidslaw.ca/Maincontent/issues/prisons/e-info-pa4.htm
2. HIV/AIDS in Prisons: Background Materials, Appendix 5. Published by the Correctional Service of Canada. For copies in English or French,
call: 613.995.5058.
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1 Antiretroviral Agents Dosing and Administration Recommendations: PIs
January 2002 Volume 5, Issue 1 visit HEPP News online at www.hivcorrections.org
Indinavir**
(Crixivan)
800mg q 8h
Separated ddI
dose by 1 hr
i77%; take 1 hr
before or 2 hours
after meals; may
take with low fat
snack or skim
milk
GI intolerance
(10-15%);
nephrolithiasis or
nephrotoxicity
(10-15%);
headache;
asthenia;
dizziness; rash;
metallic taste;
ITP; alopecia;
lab: increase
indirect
bilirubinemia
(inconsequential)
Class side
effects*
Ritonavir
(Norvir)
600mg bid
Separate ddI
dose by 2 hr
h15%; take with
food if possible
to improve toler-
ability
GI intolerance
(20-40%); pares-
thesias-circum-
oral and extremi-
ties (10%); taste
perversion
(10%);
lab:triglycerides
increase in 60%
and transami-
nase increase in
10-15%, CPK
and uric acid
increase Class
side effects*
(Invirase)
Not recommend-
ed as single PI
400mg bid with
RTV
No food effect
when taken with
RTV
GI intolerance
(10-20%);
increase Class
side effects*
Saquinavir**
(Fortovase)
1200mg tid
h6x; take with
large meal
unless taken
with RTV
GI intolerance
(20-30%);
headache;
hypoglycermia;
transaminase
increase
Class side
effects*
Amprenavir
(Agenerase)
1200mg bid
(caps)
1400mg bid
(oral solution)
high fat meal
decreases AUC
20%; can be
taken with or
without food, but
high fat meal
should be
avoided.
GI intolerance
(10-30%); rash
(20-25% - usually
at 1-10 wks),
Stevens-Johnson
syndrome (1%);
paresthesias
(10-30% -
perioral or
peripheral)
Increase in liver
function tests.
Class side
effects*
Nelfinavir
(Viracept)
1250mg bid or
750mg tid
h2-3x; take
with meal or
snack
Diarrhea
(10-30%)
Class side
effects*
Lopinavir +
Ritonavir
(Kaletra)
3 caps or 0.5mL
twice daily
4 caps bid
when used with
efavirenz or
nevirapine
Fat increases
AUC 50% to
80%; should be
taken with food
GI intolerance:
nausea, vomit-
ing, diarrhea
Elevated Lipids
Asthenia
Class side
effects*
PROTEASE INHIBITORS (PIs)
R
ec
om
m
en
de
d
D
os
e
Fo
od
Ef
fe
ct
Si
de
Ef
fe
ct
s*
*For full information on toxicity and drug interactions for PIs and class side effects, see Chapter 4 of Bartlett JG and Gallant
JE. 2001-2002 Medical Management of HIV Infection. Johns Hopkins University, Baltimore, MD. 2001.
Resources & Websites
CDC STD Prevention Website
http://www.cdc.gov/nchstp/dstd/dstdp.html
National Institutes of Allergy and Infectious Diseases (NIAID)
STD Information Page
http://www.niaid.nih.gov/daids/prevention/stds.htm
STD Fact Sheet
http://www.niaid.nih.gov/factsheets/stdinfo.htm
MEDLINE Sexually Transmitted Diseases Website
http://www.nlm.nih.gov/medlineplus/sexuallytransmitteddiseases.html
Sexually Transmitted Diseases Information Center (JAMA)
http://www.ama-assn.org/special/std/std.htm
Powerpoint presentations from the HEPP NCCHC preconference
symposium available in electronic form. Topics include: the correc-
tional side of HCV, HBV, TB, HIV in women, Mental Health in HIV-
positive patients, and information on treating Transgendered patients.
Email HEPPNews@brown.edu
HIV Treatment Resources
HIV/AIDS Annual Update 2001
A collection of 11 clinical reviews now available on medscape.
http://hiv.medscape.com/update2001
AMFAR HIV/AIDS Treatment Directory, Summer 2001 Edition
For free copies, contact Barbara Good at barbara.good@amfar.org or
fax a request to 212.806.1601
Updated Adult and Adolescent HIV Treatment Guidelines
http://www.hivatis.org/guidelines/adult/Aug13_01/pdf/AAAug13S.PDF
Adapted from Bartlett JG and Gallant JE. 2001-2002 Medical Management of HIV Infection. Johns Hopkins University,
Baltimore, MD. 2001.
This table is a replacement for the table that was printed with a copy error on page 8 of the November 2001 issue of HEPP
News. The entire Antiretroviral Agents Dosing and Administration Recommendations table is available in its correct form at
http://www.hivcorrections.org/archives/nov01/nov2001.pdf (pages 7-8) or by emailing a request to heppnews@brown.edu.
9th Conference on Retroviruses
and Opportunistic Infections
February 24-28, 2002
Seattle, Washington
Registration: Dec. 10, 2001-
Jan. 23, 2002
Call: 703.535.6899
Visit: www.retroconference.org
2002 National STD Prevention
Conference
March 4-7, 2002
San Diego, California
Fee: before Feb. 8: $140;
after Feb. 8: $165
Visit: http://www.stdconference.org/
Call: G. Vaughn, 404.639.8260
Email: ghv1@cdc.gov
Management of HIV/AIDS in the
Correctional Setting: A Live
Satellite Videoconference Series
"Dermatological Manifestations
of HIV Infection"
March 12, 2002
12:30-3:30 p.m. EST
Call: 518.262.4674
Email: ybarraj@mail.amc.edu
Visit: www.amc.edu/patient/HIV/
hivconf.htm
CME Credits Available
14th National HIV/AIDS Update
Conference (NAUC)
March 19-22, 2002
San Francisco, California
Sponsored by American
Foundation for AIDS Research
Fee: before March 1: $325;
after March 1: $375
(special rates available)
Visit: http://www.amfar.org/cgi-
bin/iowa/nauc/index.html
CME credit available
International Conference on
Emerging Infectious Diseases
March 24-27, 2002
Atlanta, Georgia
Fee: before March 4: $300;
on-site: $350
Visit: http://www.cdc.gov/iceid/
Call: C. Schable, 404.639.4581
Email: cas1@cdc.gov
Clinical Updates in
Correctional Health Care
April 13-16, 2002
Fort Lauderdale, Florida
Visit: www.ncchc.org
Fax: 773.880.2424
Save the 
Dates
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Treatment Efficacy Predicted in Six Days
Lancet 2001. 358 (9295): 1760-1765.
Findings from a new study are likely to change
the clinician’s approach to HIV management
over the course of the next year. The new study
looked at rates of change in viral load and found
that the rate of decline of a patient’s HIV after the
first six days of treatment is a good predictor of
the patient’s long term response to treatment.
Current guidelines indicate that providers should
change a patient’s treatment if the reduction in
plasma HIV RNA is less than 0.50-0.70 log after
four weeks of treatment or less than 1.00 log by
eight weeks of therapy. This study has shown
that much earlier predictions of treatment effica-
cy are possible. Critics warn that predicting
treatment efficacy after six days of treatment is
only valid if more is known about the patient’s
adherence to the drug regimen.
HAART Therapy: One Week on, One Week
Off?
NIH Release, 12/3/01
A new study from the National Institutes of
Allergy and Infectious Diseases shows that
cycling antiretroviral medications in a seven day-
on, seven day off manner appears to reduce
toxic side effects without reducing the drug’s
effectiveness. The study put 10 patients on a
“structured intermittent therapy” regimen where
they received combination therapy of stavudine,
lamivudine, indinavir, and ritonavir for seven
days followed by seven days of no medication
before beginning the next drug cycle. All of the
participants maintained their CD4+ count and
viral load levels throughout the 32-68 week
study. While there were no signs of drug-resis-
tance in these patients, there were marked
decreases in serum cholesterol and triglyceride
levels. Larger scale trials are now underway. If
these trials support the small-scale study and
prove that there are no adverse effects, drug
costs could be reduced by as much as 50%.
Results from this study are expected to be
released in February, at the annual Retrovirus
conference. Practitioners and patients are
advised to await definitive data before adopting
this approach to HIV treatment.
Condoms Available in the LA County Jail
LA Times, 11/30/01
Following the approval of the Los Angeles
County Sheriff’s Department, the Los Angeles
County Jail (LACJ) has begun distributing con-
doms to its “self-declarded” gay inmates. In the
LACJ, gay inmates are segregated into separate
housing units. Inmates are receiving condoms
through an outside agency, which provides a
weekly HIV/AIDS lecture and then distributes the
condoms. Margaret Winter of the American Civil
Liberties Union (ACLU) has said that the provi-
sion of condoms to self-declared gay men does
nothing to protect the large numbers of men who
participate in sex in prison but do not self-identi-
fy as gay. Although having sex while incarcerat-
ed is a felony under California law, the sheriff’s
office has recognized the rising number of new
HIV cases in the jail and is responding to the
health crisis. The LACJ is the seventh correc-
tional facility on the nation to begin distributing
condoms, joining four other jails in New York
City, Philadelphia, San Francisco and
Washington, and two prisons, in Vermont and
Mississippi.
Hit Hard, Hit Early Dealt Another Blow:
Delaying HAART May Be Safe
JAMA 2001. 286 (20): 2560-2567 and 2568-
2577
Continuing the recent trend in HIV management
studies, two separate studies appear to demon-
strate that delaying HAART until a patient’s
CD4+ count drops to 200 cells/mL and has a
high level of virus circulating in the bloodstream
is safe. Although it took longer for patients with
higher initial viral load levels to reach an unde-
tectable level of virus, all patients had the same
chance of having an undetectable viral load after
32 weeks of treatment. Furthermore, patients
whose CD4+ count was between 200 and 349 at
baseline fared just as well after 32 weeks of
treatment as patients whose initial levels were
higher than 350. While these findings have the
potential to change treatment recommendations,
experts caution that these results may not be the
same for all patients, especially women, who
exhibit different viral loads and may develop full-
blown AIDS at lower levels of viremia than men.
Risk of Vulvar Cancer Increased Among HIV-
Positive Women
Lancet 2002; 359:108-113
A new study conducted by researchers from
Columbia University notes that HIV-positive
women are at increased risk for vulvar cancer as
well as cervical cancer. A study group of 925
women was followed for 3 years. Women under-
went twice-yearly gynecological examinations.
At the start of the study, 6% of the 481 HIV-pos-
itive women had vulvovaginal/perianal condolo-
ma acuminata or intraepithelial neoplasia com-
pared to only 1% of the HIV-negative women.
Throughout the course of the study, HIV-positive
women who did not previously have vulvar can-
cer were 16 times more likely to develop vulvo-
vaginal or perianal lesions compared with the
HIV-negative women. Risk factors for developing
lesions included HIV infection, decreased CD4+
count, HPV infection, and a history of frequent
injection drug use.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions.
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2002.
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.True or False: Human Papilloma Virus (HPV) can be transmitted
vertically from mother to child.
a) True
b) False
2. Which of the following are high-risk subtypes of HPV (human
papilloma virus) because they are associated with cervical cancer?
a) 6, 11
b) 42, 43, 44
c) 31, 33, 35, 51, 52
d) 16, 18
e) 16, 11, 33, 52
3. Which of the following treatment modalities will eradicate HPV
(human papilloma virus)?
a) radical surgical excision
b) podophylin
c) tricloroacetic acid
d) radiation therapy
e) no treatment modality will eradicate the virus
4. For routine HPV screening, what is the current standard of prac-
tice for incarcerated HIV-positive women?
a) yearly PAP smears and visual inspection of the external
genitalia
b) twice-yearly PAP smears and visual inspection of the
external genitalia
c) PAP smears and visual inspection of the external genitalia
once every-other year
d) PAP smears and visual inspection of the external genitalia
once every three years
e) PAP smears and visual inspection of the external genitalia
once every five years
5. If a patient has started abacavir (ABC) therapy within the past
six weeks, which of the following symptoms might indicate that the
patient is suffering from abacavir hypersensitivity syndrome?
a) a skin rash, fever, and nausea that subsides in 36 hours
b) herpes simplex virus flare-up
c) a skin rash, vomiting, and insomnia
d) vivid dreams
e) a skin rash, abdominal pain, and severe fatigue that persists
beyond 72-96 hours
6. If a patient is diagnosed with abacavir hypersensitivity syndrome
(AHS), that patient should NEVER restart what type of therapy
(choose the one correct answer):
a) ABC (Abacavir or Ziagen)
b) ABC (Abacavir or Ziagen) or Trizavir (AZT/3TC/ABC))
c) AZT/3TC (Combivir)
d) DDI/D4T
e) Nelfinavir (Viracept)
BROWN MEDICAL SCHOOL • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical
education activities for physicians.
The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations
and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5 4 3 2 1 5 4 3 2 1
HEPPigram 5 4 3 2 1 5 4 3 2 1
HIV 101 5 4 3 2 1 5 4 3 2 1
Save the
Dates 5 4 3 2 1 5 4 3 2 1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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